Canada markets close in 3 hours 35 minutes

I-Mab (0VY.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
1.7100+0.0200 (+1.18%)
As of 08:02AM CET. Market open.

I-Mab

New Bund Center
55th Floor 555 West Haiyang Road Pudong District
Shanghai 200124
China
86 21 6057 8000
https://www.i-mabbiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Raj KannanCEO & DirectorN/AN/A1964
Dr. Jerry WangCo-Founder & Chief Scientific OfficerN/AN/AN/A
Mr. Skelton JosephChief Financial OfficerN/AN/AN/A
Mr. Tianyi ZhangVice President of Investor RelationsN/AN/AN/A
Mr. Cheng LiChief Legal OfficerN/AN/A1984
Ms. Gigi Qi FengChief Communications OfficerN/AN/A1981
Dr. Weiming Tang Ph.D.Executive VP of Global Business Development & Chief Business OfficerN/AN/A1966
Dr. Fernando J. Salle´s Ph.D.Senior VP and Head of U.S. & EU Business DevelopmentN/AN/AN/A
Claire XuHead of US siteN/AN/AN/A
Dr. John Hayslip M.D.Chief Medical OfficerN/AN/A1977
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Corporate Governance

I-Mab’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.